A double-blind, 12-month, placebo- and active-controlled study enrolled immunocompetent adults with a history of 6 or more recurrences per year. Outcomes for the overall study population are shown in Table 1.
*Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.
Subjects with 9 or fewer
recurrences per year showed comparable results with VALTREX 500 mg
*taken from the official pdr info on valtrex as of 6/1/07